Capstone Therapeutics Corp (CAPS) 0.0650 $CAPS
Capstone Therapeutics Announces That Its Joint Venture, LipimetiX Development, Inc., Has Closed a Series B-1 Preferred Stock Offering
GlobeNewswire - Thu Aug 25, 8:00AM CDT
Capstone Therapeutics Corp. (OTCQB:CAPS) ("the Company"
and LipimetiX Development, Inc., the Company's drug development joint venture ("JV" announced today that the JV's Series B-1 preferred stock offering totaling $1,012,000 closed on August 25, 2016. Individual accredited investors and management participated in the financing. Evolution Venture Partners, a NY-based investment bank, has been engaged to advise the JV on corporate finance matters.
Capstone Therapeutics Announces Existing Shareholder Decision Not to Extend Exclusive due Diligence Period
GlobeNewswire - Wed Feb 03, 2:29PM CST
Capstone Therapeutics Corp. (OTCQB:CAPS) ("the Company" and LipimetiX Development, Inc., the Company's 60% owned joint venture ("JV" announced today that the Lenders, as defined in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission dated December 15, 2015, informed the Company that the Lenders would not exercise their option to extend the exclusive due diligence period through March 31, 2016 by loaning Capstone a second $1 million, under the terms of the previously-reported Securities Purchase Agreement. The Company believes that this decision by the Lenders is principally due to current developments in the financial markets and is not due to the outcome of the Lenders evaluation of the JV's AEM-28-14 development program.
Capstone Therapeutics Announces Loan From Existing Shareholder for Exclusive Due Diligence Period
GlobeNewswire - Tue Dec 15, 3:15PM CST
Capstone Therapeutics Corp. (OTCQB:CAPS) ("the Company" and LipimetiX Development, Inc., the Company's 60% owned joint venture ("JV" announced today that the Biotechnology Value Fund, L.P. and other affiliates of BVF Partners L.P. ("BVF" have provided a $1 million secured loan to Company as consideration for the Company granting an exclusive period for due diligence, which may lead to an equity investment in Company of up to $10 million. For additional information, please see the Company's Current Form 8-K filed with the Securities and Exchange Commission on December 15, 2015.
Capstone Therapeutics Announces Allowance of U.S. Patent for Treatment of Diabetes With Apo E Mimetic Peptides
GlobeNewswire - Wed Oct 14, 8:00AM CDT
Capstone Therapeutics, Inc. (OTCQB:CAPS) ("the Company" and its (60% owned) joint venture affiliate, LipimetiX Development, Inc. ("JV", announced today the allowance of U.S. Patent application number 12/675,089 for the use of apolipoprotein E mimetic peptides to decrease plasma glucose in patients with diabetes or insulin resistance. In multiple animal models AEM-28, the parent peptide in the JV's Chimeric Apolipoprotein E Mimetic Peptide (CHAMP) platform, increases insulin and glucose sensitivity, decreases plasma insulin and glucose and decreases weight gain in diet induced models of type 2 diabetes. The newly allowed patent expands the utility of the CHAMP technology beyond claims in previous JV patents for the treatment of diabetic dyslipidemia and vascular diseases.
Capstone Therapeutics Announces Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides
GlobeNewswire - Thu Jul 23, 7:00AM CDT
Capstone Therapeutics Corp. (OTCQB:CAPS) ("the Company" and its joint venture affiliate, LipimetiX Development, Inc. ("JV", announced today the conversion of a provisional U.S. Patent application claiming novel, more potent analogs of its lead peptide, AEM-28. The JV has supported research by Dr. G.M. Anantharamaiah at the University of Alabama, Birmingham ("UAB" to identify novel analogs of AEM-28 that demonstrate greater efficacy than the parent peptide and provide new composition of matter patent protection. One of the new, chimeric Apo E mimetic peptides (AEM-28-14), tested in multiple, validated animal models, demonstrates up to 400% greater cholesterol lowering efficacy and a several fold increase in the NOAEL (No Observed Adverse Effect Level) dose, a primary indicator of drug tolerability. The combination of enhanced efficacy and toleration potentially increases the therapeutic window (the range for delivering a safe and efficacious dose) significantly over previous analogs of AEM-28.
Capstone Therapeutics Announces Settlement of Qui Tam Lawsuit
GlobeNewswire - Tue Jun 02, 7:00AM CDT
Capstone Therapeutics (OCTQB:CAPS) (the "Company" today announced settlement and dismissal of the ongoing qui tam lawsuit initially filed in 2005 against OrthoLogic Corp., the Company's previous corporate name. The qui tam action named as defendants substantially all sellers of bone growth stimulation devices during the period 1998-2003 and asserted a variety of claims, including False Claims Act violations. The Company sold its bone growth stimulation device business in 2003 and did not learn of this lawsuit until September 2009. The case has continued for an additional six years.
Capstone Therapeutics Announces First Quarter 2015 Financial Results and Operating Update Conference Call
GlobeNewswire - Fri May 22, 10:00AM CDT
Capstone Therapeutics (OTCQB:CAPS); (the "Company", will hold a conference call and webcast on Thursday, May 28, 2015 at 4:30 pm EDT. The call may be accessed at 877-303-2908 (U.S.), 408-427-3860 (outside U.S.); accompanying slides may be viewed by logging onto the Investors section of the Company's website, www.capstonethx.com. A replay will be available beginning May 28, 2015 at 7:30 pm EDT until midnight May 31, 2015, and may be accessed at 855-859-2056 (U.S.) or 404-537-3406 (outside U.S.) with conference ID 52304334.
Capstone Therapeutics, Inc. - "Following the Data"
ACCESSWIRE - Mon Apr 27, 7:05AM CDT
NEW YORK, NY / ACCESSWIRE / April 27, 2015 / Capstone Therapeutics (OTCQB:CAPS) today published a new blog post on The Chairman's Blog, written by the Company's Executive Chairman and CEO, Jock Holliman, and President of LipimetiX Development, LLC, Dennis I. Goldberg, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Capstone Therapeutics Announces Operating Update Conference Call
GlobeNewswire - Fri Mar 20, 10:00AM CDT
Capstone Therapeutics (OTCQB:CAPS); (the "Company", will hold a conference call and webcast on Thursday, March 26, 2015 at 4:30 pm EDT. The call may be accessed at 877-303-2908 (U.S.), 408-427-3860 (outside U.S.); accompanying slides may be viewed by logging onto the Investors section of the Company's website, www.capstonethx.com. A replay will be available beginning March 26, 2015 at 7:30 pm EDT until midnight March 29, 2015, and may be accessed at 855-859-2056 (U.S.) or 404-537-3406 (outside U.S.) with conference ID 9888102.
Capstone Could Succeed with AEM-28 Where Aegerion and Sanofi Failed
ACCESSWIRE - Wed Jan 28, 8:01AM CST
NEW YORK, NY / ACCESSWIRE / January 28, 2015 / Cholesterol-reducing statins like Pfizer's (NYSE
FE) Lipitor may be the best selling prescription drug class in history, but for one kind of cholesterol disease, statins are just a pharmacological drop in the bucket.
PFE: 34.26 (+0.11), AEGR: 2.75 (+0.10), SNY: 38.35 (-0.22)
Capstone Therapeutics, Inc. - "Importance of VLDL and Triglycerides in Cardiovascular Disease"
ACCESSWIRE - Tue Dec 16, 11:49AM CST
New York, NY / ACCESSWIRE / December 16, 2014 / Capstone Therapeutics (OTCQB:CAPS) today published a new blog post on The Chairman's Blog, written by the Company's Executive Chairman and Principal Executive Officer, John Holliman, III. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Capstone Therapeutics Announces Phase 1b/2a Study Results for AEM-28 Showing Safety and Biomarker Efficacy Signals
GlobeNewswire - Tue Dec 16, 7:37AM CST
Capstone Therapeutics (OTCQB:CAPS) ("the Company" and its joint venture affiliate, LipimetiX Development, LLC ("JV", announced today the completion of and results for its investigational AEM-28 (Apo E mimetic peptide) Phase 1b/2a human clinical trial in cholesterol and lipid reduction. The top-line data from the Phase 1a (reported on September 2, 2014) and Phase 1b/2a blended protocol has been analyzed. The Medical Safety Committee, reviewing all safety-related aspects of the clinical trial, observed a generally acceptable safety profile. As a first-in-man study, the primary endpoint was safety; yet, efficacy measurements analyzing pharmacodynamics yielded statistical significance in the pooled dataset favoring AEM-28 versus placebo in multiple lipid biomarker endpoints, which included:
Capstone Therapeutics Will Provide an Operating Update and Announces Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 13, 8:00AM CST
Capstone Therapeutics (OTCQB:CAPS); (the "Company", today will hold a conference call and webcast to provide an operating update and announced financial results for the third quarter 2014.
Capstone Therapeutics Announces Third Quarter 2014 Financial Results and Operating Update Conference Call
GlobeNewswire - Thu Nov 06, 9:00AM CST
Capstone Therapeutics (OTCQB:CAPS); (the "Company", will hold a conference call and webcast on Thursday, November 13, 2014 at 4:30 pm EST. The call may be accessed at 877-303-2908 (U.S.), 408-427-3860 (outside U.S.); accompanying slides may be viewed by logging onto the Investors section of the Company's website, www.capstonethx.com. A replay will be available beginning November 13, 2014 at 7:30 pm EST until midnight November 16, 2014, and may be accessed at 855-859-2056 (U.S.) or 404-537-3406 (outside U.S.) with conference ID 22735607.
Capstone Therapeutics, Inc. - "AEM-28 Drug Class May Serve Larger Cardiovascular Markets"
ACCESSWIRE - Tue Oct 07, 7:51AM CDT
New York, NY / October 7, 2014 / Capstone Therapeutics (OTCQB: CAPS) today published a new blog post on The Chairman's Blog, written by the Company's Executive Chairman and Principal Executive Officer, John Holliman, III. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Capstone Therapeutics Announces That Its Joint Venture, LipimetiX Development, Inc., Has Closed a Series B-1 Preferred Stock Offering
GlobeNewswire - Thu Aug 25, 8:00AM CDT
Capstone Therapeutics Corp. (OTCQB:CAPS) ("the Company"
and LipimetiX Development, Inc., the Company's drug development joint venture ("JV" announced today that the JV's Series B-1 preferred stock offering totaling $1,012,000 closed on August 25, 2016. Individual accredited investors and management participated in the financing. Evolution Venture Partners, a NY-based investment bank, has been engaged to advise the JV on corporate finance matters. Capstone Therapeutics Announces Existing Shareholder Decision Not to Extend Exclusive due Diligence Period
GlobeNewswire - Wed Feb 03, 2:29PM CST
Capstone Therapeutics Corp. (OTCQB:CAPS) ("the Company"
and LipimetiX Development, Inc., the Company's 60% owned joint venture ("JV" announced today that the Lenders, as defined in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission dated December 15, 2015, informed the Company that the Lenders would not exercise their option to extend the exclusive due diligence period through March 31, 2016 by loaning Capstone a second $1 million, under the terms of the previously-reported Securities Purchase Agreement. The Company believes that this decision by the Lenders is principally due to current developments in the financial markets and is not due to the outcome of the Lenders evaluation of the JV's AEM-28-14 development program. Capstone Therapeutics Announces Loan From Existing Shareholder for Exclusive Due Diligence Period
GlobeNewswire - Tue Dec 15, 3:15PM CST
Capstone Therapeutics Corp. (OTCQB:CAPS) ("the Company"
and LipimetiX Development, Inc., the Company's 60% owned joint venture ("JV" announced today that the Biotechnology Value Fund, L.P. and other affiliates of BVF Partners L.P. ("BVF" have provided a $1 million secured loan to Company as consideration for the Company granting an exclusive period for due diligence, which may lead to an equity investment in Company of up to $10 million. For additional information, please see the Company's Current Form 8-K filed with the Securities and Exchange Commission on December 15, 2015. Capstone Therapeutics Announces Allowance of U.S. Patent for Treatment of Diabetes With Apo E Mimetic Peptides
GlobeNewswire - Wed Oct 14, 8:00AM CDT
Capstone Therapeutics, Inc. (OTCQB:CAPS) ("the Company"
and its (60% owned) joint venture affiliate, LipimetiX Development, Inc. ("JV", announced today the allowance of U.S. Patent application number 12/675,089 for the use of apolipoprotein E mimetic peptides to decrease plasma glucose in patients with diabetes or insulin resistance. In multiple animal models AEM-28, the parent peptide in the JV's Chimeric Apolipoprotein E Mimetic Peptide (CHAMP) platform, increases insulin and glucose sensitivity, decreases plasma insulin and glucose and decreases weight gain in diet induced models of type 2 diabetes. The newly allowed patent expands the utility of the CHAMP technology beyond claims in previous JV patents for the treatment of diabetic dyslipidemia and vascular diseases. Capstone Therapeutics Announces Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides
GlobeNewswire - Thu Jul 23, 7:00AM CDT
Capstone Therapeutics Corp. (OTCQB:CAPS) ("the Company"
and its joint venture affiliate, LipimetiX Development, Inc. ("JV", announced today the conversion of a provisional U.S. Patent application claiming novel, more potent analogs of its lead peptide, AEM-28. The JV has supported research by Dr. G.M. Anantharamaiah at the University of Alabama, Birmingham ("UAB" to identify novel analogs of AEM-28 that demonstrate greater efficacy than the parent peptide and provide new composition of matter patent protection. One of the new, chimeric Apo E mimetic peptides (AEM-28-14), tested in multiple, validated animal models, demonstrates up to 400% greater cholesterol lowering efficacy and a several fold increase in the NOAEL (No Observed Adverse Effect Level) dose, a primary indicator of drug tolerability. The combination of enhanced efficacy and toleration potentially increases the therapeutic window (the range for delivering a safe and efficacious dose) significantly over previous analogs of AEM-28. Capstone Therapeutics Announces Settlement of Qui Tam Lawsuit
GlobeNewswire - Tue Jun 02, 7:00AM CDT
Capstone Therapeutics (OCTQB:CAPS) (the "Company"
today announced settlement and dismissal of the ongoing qui tam lawsuit initially filed in 2005 against OrthoLogic Corp., the Company's previous corporate name. The qui tam action named as defendants substantially all sellers of bone growth stimulation devices during the period 1998-2003 and asserted a variety of claims, including False Claims Act violations. The Company sold its bone growth stimulation device business in 2003 and did not learn of this lawsuit until September 2009. The case has continued for an additional six years. Capstone Therapeutics Announces First Quarter 2015 Financial Results and Operating Update Conference Call
GlobeNewswire - Fri May 22, 10:00AM CDT
Capstone Therapeutics (OTCQB:CAPS); (the "Company"
, will hold a conference call and webcast on Thursday, May 28, 2015 at 4:30 pm EDT. The call may be accessed at 877-303-2908 (U.S.), 408-427-3860 (outside U.S.); accompanying slides may be viewed by logging onto the Investors section of the Company's website, www.capstonethx.com. A replay will be available beginning May 28, 2015 at 7:30 pm EDT until midnight May 31, 2015, and may be accessed at 855-859-2056 (U.S.) or 404-537-3406 (outside U.S.) with conference ID 52304334. Capstone Therapeutics, Inc. - "Following the Data"
ACCESSWIRE - Mon Apr 27, 7:05AM CDT
NEW YORK, NY / ACCESSWIRE / April 27, 2015 / Capstone Therapeutics (OTCQB:CAPS) today published a new blog post on The Chairman's Blog, written by the Company's Executive Chairman and CEO, Jock Holliman, and President of LipimetiX Development, LLC, Dennis I. Goldberg, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Capstone Therapeutics Announces Operating Update Conference Call
GlobeNewswire - Fri Mar 20, 10:00AM CDT
Capstone Therapeutics (OTCQB:CAPS); (the "Company"
, will hold a conference call and webcast on Thursday, March 26, 2015 at 4:30 pm EDT. The call may be accessed at 877-303-2908 (U.S.), 408-427-3860 (outside U.S.); accompanying slides may be viewed by logging onto the Investors section of the Company's website, www.capstonethx.com. A replay will be available beginning March 26, 2015 at 7:30 pm EDT until midnight March 29, 2015, and may be accessed at 855-859-2056 (U.S.) or 404-537-3406 (outside U.S.) with conference ID 9888102. Capstone Could Succeed with AEM-28 Where Aegerion and Sanofi Failed
ACCESSWIRE - Wed Jan 28, 8:01AM CST
NEW YORK, NY / ACCESSWIRE / January 28, 2015 / Cholesterol-reducing statins like Pfizer's (NYSE
FE) Lipitor may be the best selling prescription drug class in history, but for one kind of cholesterol disease, statins are just a pharmacological drop in the bucket. PFE: 34.26 (+0.11), AEGR: 2.75 (+0.10), SNY: 38.35 (-0.22)
Capstone Therapeutics, Inc. - "Importance of VLDL and Triglycerides in Cardiovascular Disease"
ACCESSWIRE - Tue Dec 16, 11:49AM CST
New York, NY / ACCESSWIRE / December 16, 2014 / Capstone Therapeutics (OTCQB:CAPS) today published a new blog post on The Chairman's Blog, written by the Company's Executive Chairman and Principal Executive Officer, John Holliman, III. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Capstone Therapeutics Announces Phase 1b/2a Study Results for AEM-28 Showing Safety and Biomarker Efficacy Signals
GlobeNewswire - Tue Dec 16, 7:37AM CST
Capstone Therapeutics (OTCQB:CAPS) ("the Company"
and its joint venture affiliate, LipimetiX Development, LLC ("JV", announced today the completion of and results for its investigational AEM-28 (Apo E mimetic peptide) Phase 1b/2a human clinical trial in cholesterol and lipid reduction. The top-line data from the Phase 1a (reported on September 2, 2014) and Phase 1b/2a blended protocol has been analyzed. The Medical Safety Committee, reviewing all safety-related aspects of the clinical trial, observed a generally acceptable safety profile. As a first-in-man study, the primary endpoint was safety; yet, efficacy measurements analyzing pharmacodynamics yielded statistical significance in the pooled dataset favoring AEM-28 versus placebo in multiple lipid biomarker endpoints, which included: Capstone Therapeutics Will Provide an Operating Update and Announces Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 13, 8:00AM CST
Capstone Therapeutics (OTCQB:CAPS); (the "Company"
, today will hold a conference call and webcast to provide an operating update and announced financial results for the third quarter 2014. Capstone Therapeutics Announces Third Quarter 2014 Financial Results and Operating Update Conference Call
GlobeNewswire - Thu Nov 06, 9:00AM CST
Capstone Therapeutics (OTCQB:CAPS); (the "Company"
, will hold a conference call and webcast on Thursday, November 13, 2014 at 4:30 pm EST. The call may be accessed at 877-303-2908 (U.S.), 408-427-3860 (outside U.S.); accompanying slides may be viewed by logging onto the Investors section of the Company's website, www.capstonethx.com. A replay will be available beginning November 13, 2014 at 7:30 pm EST until midnight November 16, 2014, and may be accessed at 855-859-2056 (U.S.) or 404-537-3406 (outside U.S.) with conference ID 22735607. Capstone Therapeutics, Inc. - "AEM-28 Drug Class May Serve Larger Cardiovascular Markets"
ACCESSWIRE - Tue Oct 07, 7:51AM CDT
New York, NY / October 7, 2014 / Capstone Therapeutics (OTCQB: CAPS) today published a new blog post on The Chairman's Blog, written by the Company's Executive Chairman and Principal Executive Officer, John Holliman, III. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
